Terlipressin Administration in Septic Shock Refractory to Catecholamines
Launched by ASSAF-HAROFEH MEDICAL CENTER · Nov 18, 2008
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • septic shock patients receiving above 0.5 mcg/kg NA
- Exclusion Criteria:
- • allergy to terlipressin, CHF, IHD, pregnancy
About Assaf Harofeh Medical Center
Assaf-Harofeh Medical Center is a prominent healthcare institution located in Israel, renowned for its commitment to advancing medical research and improving patient care. As a key sponsor of clinical trials, the center focuses on a diverse range of therapeutic areas, leveraging its state-of-the-art facilities and interdisciplinary expertise to facilitate innovative studies. With a dedicated team of experienced researchers and clinicians, Assaf-Harofeh Medical Center is dedicated to fostering scientific breakthroughs that enhance treatment outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zrifin, , Israel
Patients applied
Trial Officials
Tal Mann, Dr
Study Director
Asaf Harofeh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials